psalexa
logo

Dermatology Drug Market

Global Dermatology Drug Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10496
Available Format:

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Dermatological Disease

1.3.2. Market Segmentation by Drug Classification

1.3.3. Market Segmentation by Brand

1.3.4. Market Segmentation by Geography

1.3.5. Analysis Period

1.3.6. Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By region

2.2.1.2. By industry participants

2.2.1.3. By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Dermatological Disease

4.1.1.1. Acne

4.1.1.2. Dermatitis

4.1.1.3. Psoriasis

4.1.1.4. Skin Cancer

4.1.1.5. Rosacea

4.1.1.6. Alopecia

4.1.1.7. Others

4.1.2. Overview by Drug Classification

4.1.2.1. Prescription-Based Drugs

4.1.2.2. Over-the-Counter Drugs

4.1.3. Overview by Brand

4.1.3.1. Humira

4.1.3.2. Stelara

4.1.3.3. Enbrel

4.1.3.4. Cubicin

4.1.3.5. Zyvox

4.1.3.6. Solodyn

4.1.3.7. Aczone

4.1.3.8. Protopic

4.1.3.9. Elidel

4.1.3.10. Remicade

4.1.3.11. Daivobet

4.1.3.12. Soriatane

4.1.3.13. Valtrex

4.1.3.14. Canesten

4.1.3.15. Bactroban

4.1.3.16. Others

4.2. Value Chain Analysis

4.3. Market Dynamics

4.3.1. Trends

4.3.2. Drivers

4.3.2.1. Impact analysis of drivers on market forecast

4.3.3. Restraints

4.3.3.1. Impact analysis of restraints on market forecast

4.3.4. Opportunities

4.4. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Dermatological Disease

5.1. Acne

5.2. Dermatitis

5.3. Psoriasis

5.4. Skin Cancer

5.5. Rosacea

5.6. Alopecia

5.7. Others

Chapter 6. Market Size and Forecast by Drug Classification

6.1. Prescription-Based Drugs

6.2. Over-the-Counter Drugs

Chapter 7. Market Size and Forecast by Brand

7.1. Humira

7.2. Stelara

7.3. Enbrel

7.4. Cubicin

7.5. Zyvox

7.6. Solodyn

7.7. Aczone

7.8. Protopic

7.9. Elidel

7.10. Remicade

7.11. Daivobet

7.12. Soriatane

7.13. Valtrex

7.14. Canesten

7.15. Bactroban

7.16. Others

Chapter 8. Market Size and Forecast by Geography

8.1. North America Dermatology Drug Market

8.1.1. By Dermatological Disease

8.1.2. By Drug Classification

8.1.3. By Brand

8.1.4. By Country-The U.S, and Canada

8.2. Western Europe Dermatology Drug Market

8.2.1. By Dermatological Disease

8.2.2. By Drug Classification

8.2.3. By Brand

8.2.4. By Country –Germany, France, U.K and Rest of Western Europe

8.3.  Central and Eastern Europe Dermatology Drug Market

8.3.1. By Dermatological Disease

8.3.2. By Drug Classification

8.3.3. By Brand

8.3.4. By Country –Russia and Rest of Central and Eastern Europe

8.4.  Asia-Pacific Dermatology Drug Market

8.4.1. By Dermatological Disease

8.4.2. By Drug Classification

8.4.3. By Brand

8.4.4. By Country -China, Japan, India and Rest of Asia-Pacific

8.5. Latin America Dermatology Drug Market

8.5.1. By Dermatological Disease

8.5.2. By Drug Classification

8.5.3. By Brand

8.5.4. By Country –Brazil and Rest of Latin America

8.6. Middle East & Africa (MEA) Dermatology Drug Market

8.6.1. By Dermatological Disease

8.6.2. By Drug Classification

8.6.3. By Brand

8.6.4. By Country –South Africa and MEA

Chapter 9. Competitive Landscape

9.1. Competitive Analysis of Key Players

9.2. Global Strategic Developments

Chapter 10. Company Profiles

10.1. AbbVie, Inc.

10.1.1. Business Overview

10.1.2. Product and Service Offerings

10.1.3. Key Financial Summary

10.1.4. Strategic Growth Plan

10.2. Galderma S.A.

10.2.1. Business Overview

10.2.2. Product and Service Offerings

10.2.3. Key Financial Summary

10.2.4. Strategic Growth Plan

10.3. GlaxoSmithKline plc

10.3.1. Business Overview

10.3.2. Product and Service Offerings

10.3.3. Key Financial Summary

10.3.4. Strategic Growth Plan

10.4. Johnson & Johnson

10.4.1. Business Overview

10.4.2. Product and Service Offerings

10.4.3. Key Financial Summary

10.4.4. Strategic Growth Plan

10.5. LEO Pharma A/S

10.5.1. Business Overview

10.5.2. Product and Service Offerings

10.5.3. Key Financial Summary

10.5.4. Strategic Growth Plan

10.6.  Pfizer Inc.

10.6.1. Business Overview

10.6.2. Product and Service Offerings

10.6.3. Key Financial Summary

10.6.4. Strategic Growth Plan

10.7. Amgen Inc.

10.7.1. Business Overview

10.7.2. Product and Service Offerings

10.7.3. Key Financial Summary

10.7.4. Strategic Growth Plan

10.8.  Bayer AG

10.8.1. Business Overview

10.8.2. Product and Service Offerings

10.8.3. Key Financial Summary

10.8.4. Strategic Growth Plan

10.9. Bristol-Myers Squibb Company

10.9.1. Business Overview

10.9.2. Product and Service Offerings

10.9.3. Key Financial Summary

10.9.4. Strategic Growth Plan

10.10.  Mylan N.V

10.10.1. Business Overview

10.10.2. Product and Service Offerings

10.10.3. Key Financial Summary

10.10.4. Strategic Growth Plan

10.11.  Novartis AG

10.11.1. Business Overview

10.11.2. Product and Service Offerings

10.11.3. Key Financial Summary

10.11.4. Strategic Growth Plan

10.12. Pierre Fabre

10.12.1. Business Overview

10.12.2. Product and Service Offerings

10.12.3. Key Financial Summary

10.12.4. Strategic Growth Plan

10.13. Merz Pharma GmbH & Co. KGa

10.13.1. Business Overview

10.13.2. Product and Service Offerings

10.13.3. Key Financial Summary

10.13.4. Strategic Growth Plan

10.14. Merck & Co., Inc.

10.14.1. Business Overview

10.14.2. Product and Service Offerings

10.14.3. Key Financial Summary

10.14.4. Strategic Growth Plan

10.15. Biofrontera Pharmaceuticals AG

10.15.1. Business Overview

10.15.2. Product and Service Offerings

10.15.3. Key Financial Summary

10.15.4. Strategic Growth Plan

10.16. Valeant Pharmaceuticals International, Inc.

10.16.1. Business Overview

10.16.2. Product and Service Offerings

10.16.3. Key Financial Summary

10.16.4. Strategic Growth Plan

*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.

Chapter 11. Appendix

11.1. Abbreviations

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry